Intrexon | XON - Sales Revenues


Intrexon reported $717K in Sales Revenues for its fiscal quarter ending in June of 2024.





Sales Change Date
Agenus USD 24.07M 2.77M Mar/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
Amgen USD 9.9B 340M Dec/2025
Anika Therapeutics USD 26.17M 12.58M Mar/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Heron Therapeutics USD 32.81M 3.21M Sep/2024
Incyte USD 1.51B 140M Dec/2025
Intrexon USD 717K 511K Jun/2024
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
MacroGenics USD 72.84M 50.6M Sep/2025
MannKind USD 111.96M 29.83M Dec/2025
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.91B 144M Sep/2025
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Thermo Fisher Scientific USD 12.21B 1.09B Dec/2025
Veracyte USD 140.6M 8.7M Dec/2025
Xencor USD 28.24M 7.24M Dec/2025